Skip to main content
TipRanks
Go Ultimate75% OFF

Cyanotech (CYAN) AI Stock Analysis

78 Followers
CYAN

Cyanotech

(Other OTC:CYAN)

Select Model
Rating:44Neutral
Price Target:$0.52â–¼(-6.43% Downside)
Action:reiterated
Date:11/12/26

The score is primarily held back by weak financial performance—CYAN is still unprofitable with thin/volatile cash flow and rising leverage despite early operational improvement. Technicals are broadly neutral and do not strongly reinforce an uptrend. Valuation is also constrained by a negative P/E and no indicated dividend yield.

Positive Factors
Revenue StabilizationRevenue growth has returned after the 2024 trough, indicating that demand for Cyanotech’s products has stabilized and modestly expanded. Continued top-line improvement would provide a foundation for better operating leverage and support the company’s efforts to convert improving sales into sustainable profitability.
Negative Factors
Persistent Net LossesDespite substantial improvement from the 2024 loss, Cyanotech has not yet reached net profitability. Continued losses indicate that operating improvements remain insufficient to cover the full cost base, limiting retained capital and making sustained earnings generation an unresolved fundamental challenge.

Cyanotech (CYAN) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%60%80%CYAN+18.14%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$4.07M
Dividend Yield
―
Average Volume (3M)
9,771
Price to Earnings (P/E)
5.0
Beta (1Y)
0.44
Revenue Growth
11.67%
EPS Growth
―
Country
US
Employees
83
Sector
Consumer Defensive
Sector Strength
62
Industry
Packaged Foods

Cyanotech Business Overview & Revenue Model

Company Description

Established in 1983 and headquartered in Kailua-Kona, Hawaii, Cyanotech Corporation specializes in the global cultivation, processing, and distribution of natural products derived from microalgae. Its key product offerings include BioAstin Hawaiian A...

How the Company Makes Money

Cyanotech makes money primarily by producing and selling microalgae-based products through two main commercial paths: (1) bulk ingredient sales and (2) branded/packaged consumer products. Bulk ingredient revenue comes from supplying natural astaxanth...

Cyanotech Earnings Call Summary

Earnings Call Date:Nov 12, 2024(Q2-2025)|% Change Since:1.82%|Next Earnings Date:Aug 13, 2019
Earnings Call SentimentNeutral

The earnings call presented a mixed picture with notable growth in contract extraction revenue and improved inventory and capital metrics. However, significant declines in net sales, gross profit margin, and an increased net loss, largely due to inventory challenges, highlight ongoing challenges.

Positive Updates

Increase in Work-in-progress Inventory
Mid-quarter financing allowed Cyanotech to increase work in progress inventory by $1.9 million, despite a decrease in finished goods inventory.

Negative Updates

Decrease in Total Net Sales
Total net sales for the second quarter of fiscal 2025 were $5.8 million, down from $6.4 million in the same quarter of fiscal 2024, marking a decrease of $528,000 or 8.3%.

Company Guidance

In the earnings call for Cyanotech's Q2 2025, management highlighted several key metrics and provided guidance on future performance. Despite a 39% increase in bulk inventory sales and a 156% rise in contract extraction revenue, overall sales for the quarter dropped by 8% due to a 21% decline in packaged goods sales caused by stock shortages. For the first half of the year, sales were up by 2%. Total net sales for the quarter were $5.8 million, down from $6.4 million in Q2 2024, with a gross profit margin declining from 32.8% to 25.3%, driven by a higher sales mix of lower-margin bulk products. Operating loss increased to $975,000 from $632,000 in the previous year, and net loss was $1.15 million or $0.16 per diluted share, compared to $0.8 million or $0.13 per share in Q2 2024. The company reported cash reserves of $780,000 and an improved working capital of $550,000, attributed to higher inventories and a short-term debt reclassification. Management is focused on addressing inventory challenges to improve the sales mix and maintain strong sales in their algae-based products.

Cyanotech Financial Statement Overview

Summary

Fundamentals show a turnaround-in-progress but still weak overall: revenue is modestly improving, margins have rebounded, and EBITDA/free cash flow turned slightly positive in 2026. However, the company remains net loss-making, cash generation is thin/fragile, and leverage has risen as equity eroded—keeping financial risk elevated.

Income Statement

34Negative

Balance Sheet

38Negative

Cash Flow

33Negative
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue14.43M26.59M24.21M23.07M23.18M35.97M
Gross Profit6.31M8.67M6.88M5.95M7.26M13.57M
EBITDA2.35M1.31M-629.00K-2.51M-825.00K4.50M
Net Income1.18M-1.28M-3.20M-5.27M-3.44M2.15M
Balance Sheet
Total Assets23.78M22.13M23.49M25.11M29.73M32.05M
Cash, Cash Equivalents and Short-Term Investments770.00K810.00K257.00K707.00K974.00K2.59M
Total Debt11.14M11.60M11.56M10.90M11.17M9.00M
Total Liabilities14.48M14.46M14.61M13.30M13.38M12.56M
Stockholders Equity9.30M7.66M8.88M11.81M16.35M19.49M
Cash Flow
Free Cash Flow126.00K92.00K-1.44M-836.00K-3.17M1.11M
Operating Cash Flow553.00K234.00K-1.19M-455.00K-2.10M2.38M
Investing Cash Flow-427.00K-142.00K-247.00K-381.00K-1.07M-1.27M
Financing Cash Flow-166.00K461.00K990.00K569.00K1.55M-2.29M

Cyanotech Technical Analysis

Technical Analysis SentimentPositive
Last Price0.56

Price Trends

50DMA0.54Positive
100DMA0.52Positive
200DMA0.46Positive

Market Momentum

MACD-0.01Negative
RSI50.53Neutral
STOCH89.33Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYAN, the sentiment is Positive. The current price of 0.56 is above the 20-day moving average (MA) of 0.55, above the 50-day MA of 0.54, and above the 200-day MA of 0.46, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.53 is Neutral, neither overbought nor oversold. The STOCH value of 89.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYAN.

Cyanotech Risk Analysis

Cyanotech disclosed 30 risk factors in its most recent earnings report. Cyanotech reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Cyanotech Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

CYAN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SENEASENEA67Neutral$1.25B10.8315.60%―12.06%100.56%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
NATRNATR53Neutral$179.01M12.448.76%―1.21%0.20%
USNAUSNA52Neutral$250.89M-11.84-3.98%―-0.78%-228.47%
LSFLSF47Neutral$23.41M-7.89-0.17%―129.59%-31.72%
CYANCYAN44Neutral$4.14M5.0510.05%―11.67%―
HAINHAIN41Neutral$9.62M-0.03-140.07%―-18.74%45.19%

* Consumer Defensive Sector Average

Performance Comparison

-50%0%50%CYANNATRSENEAHAINUSNALSFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CYAN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CYANCyanotech Corporation0.560.1640.00%
NATRNature's Sunshine Products10.33-9.53-47.99%
SENEASeneca Foods37.2212.8852.94%
HAINThe Hain Celestial0.10-1.09-91.25%
USNAUSANA Health Sciences Inc13.57-5.14-27.47%
LSFLaird Superfood, Inc.2.08-0.52-20.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026